// App-Quantinova.ai

BSH19‐EP‐047 : Response of Velcade Dexamethasone Thalidomide (VTD) Chemotherapy in patients suitable for Autologous Stem Cell transplant in Myeloma; experience of District General Hospital

Researchers

Presenter

  • H. Vijayenthiran

Principal Investigators

  • C. Wenban

  • A. Careless

  • L. Stimson

  • H. Ahmad

Medical Centers

  • Haematology, University Hospitals Derby and Burton ‐ Queens Burton, Derby

  • Haematology, University of Leicester Hospitals, Leicester, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Central Nervous System (CNS)

  • Peripheral Nervous System

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Renal insufficiency

  • Peripheral neuropathy

  • Stroke

Biomarkers

  • Cluster of differentiation 79A

  • Immunoglobulin G

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Thalidomide

  • Bortezomib

  • Lanthanum carbonate

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved